Schirrmacher

462 total citations
28 papers, 388 citations indexed

About

Schirrmacher is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Schirrmacher has authored 28 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 10 papers in Oncology and 9 papers in Genetics. Recurrent topics in Schirrmacher's work include Virus-based gene therapy research (8 papers), Immunotherapy and Immune Responses (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Schirrmacher is often cited by papers focused on Virus-based gene therapy research (8 papers), Immunotherapy and Immune Responses (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Schirrmacher collaborates with scholars based in Germany, Italy and United States. Schirrmacher's co-authors include Hans Wigzell, Israël Vlodavsky, Zvi Fuks, Yafa Ariav, D. Komitowski, Elke Lang, Georg Brunner, D. Kramer, Philippe Fournier and Anne‐Sophie Arnold and has published in prestigious journals such as International Journal of Oncology, International Journal of Oncology and Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie.

In The Last Decade

Schirrmacher

28 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Schirrmacher Germany 12 180 131 110 106 61 28 388
I Givol United States 8 112 0.6× 106 0.8× 283 2.6× 138 1.3× 66 1.1× 10 515
R Khiroya United States 11 271 1.5× 135 1.0× 137 1.2× 61 0.6× 49 0.8× 14 502
R Bonifer Germany 8 193 1.1× 131 1.0× 96 0.9× 80 0.8× 88 1.4× 10 386
Zane C. Neal United States 12 255 1.4× 62 0.5× 162 1.5× 167 1.6× 34 0.6× 17 445
Takehiko Tachibana Japan 12 164 0.9× 47 0.4× 172 1.6× 115 1.1× 39 0.6× 48 401
N Lohrey United States 8 184 1.0× 119 0.9× 219 2.0× 56 0.5× 37 0.6× 10 486
Elisabetta Sporeno Italy 12 168 0.9× 189 1.4× 338 3.1× 226 2.1× 224 3.7× 18 778
S S Yu South Korea 13 122 0.7× 142 1.1× 177 1.6× 137 1.3× 47 0.8× 22 402
M. Kathryn Liszewski United States 11 67 0.4× 176 1.3× 252 2.3× 99 0.9× 62 1.0× 12 396
M. Wright United States 7 154 0.9× 169 1.3× 362 3.3× 110 1.0× 34 0.6× 9 484

Countries citing papers authored by Schirrmacher

Since Specialization
Citations

This map shows the geographic impact of Schirrmacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Schirrmacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Schirrmacher more than expected).

Fields of papers citing papers by Schirrmacher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Schirrmacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Schirrmacher. The network helps show where Schirrmacher may publish in the future.

Co-authorship network of co-authors of Schirrmacher

This figure shows the co-authorship network connecting the top 25 collaborators of Schirrmacher. A scholar is included among the top collaborators of Schirrmacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Schirrmacher. Schirrmacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schirrmacher. (2009). Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. International Journal of Oncology. 34(4). 951–62. 17 indexed citations
2.
Fournier, Philippe, Anne‐Sophie Arnold, & Schirrmacher. (2009). Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus.. PubMed. 14 Suppl 1. S111–22. 16 indexed citations
3.
Schirrmacher. (2009). Expression of RIG-I, IRF3, IFN-β and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. International Journal of Oncology. 34(4). 971–82. 68 indexed citations
4.
Schirrmacher. (2000). [Anti-tumor vaccination].. Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie. 125 Suppl 1. 33–6. 1 indexed citations
5.
Hagmüller, E., Naomi Beck, D. Ockert, & Schirrmacher. (1995). [Adjuvant therapy of liver metastases: active specific immunotherapy].. PubMed. 120(10). 780–5. 4 indexed citations
6.
Gabriele, Lucia, Enrico Proietti, Giampaolo Greco, et al.. (1993). Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.. PubMed. 13(3). 147–62. 4 indexed citations
7.
Kaufmann, Andreas M., et al.. (1993). Transforming growth factor-beta production and induction of cellular responses in 13762NF rat mammary adenocarcinoma cell clones.. PubMed. 13(5). 244–52. 1 indexed citations
8.
Schirrmacher. (1992). Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. International Journal of Oncology. 33(4). 823–32. 29 indexed citations
9.
Schirrmacher. (1992). Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines.. PubMed. 13. 129–54. 21 indexed citations
10.
Walter, Jürgen, Jürgen Wolf, Michael Pawlita, et al.. (1991). [Invasive, metastatic growth of lymphoblastoid B cells in immunodeficient SCID mice].. PubMed. 75. 224–8. 2 indexed citations
11.
Schirrmacher, et al.. (1989). Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells.. PubMed. 288. 391–9. 1 indexed citations
12.
Riethmüller, G., et al.. (1989). Tumor immunology: Paul Ehrlich's heritage.. PubMed. 10(8). S35–7. 12 indexed citations
13.
Lang, Elke, et al.. (1988). Changes in tumor cell adhesiveness affecting speed of dissemination and mode of metastatic growth.. PubMed. 8(3). 159–76. 38 indexed citations
14.
Schirrmacher. (1984). Cancer metastasis and the use of animal model systems.. PubMed. 195–200. 1 indexed citations
15.
Vlodavsky, Israël, Schirrmacher, Yafa Ariav, & Zvi Fuks. (1983). Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: attachment, invasion and morphological appearance.. PubMed. 3(2). 81–97. 40 indexed citations
16.
Schirrmacher, Phillip J. Robinson, Peter Altevogt, et al.. (1981). Clonal analysis of H-2 antigen expression by variants of a chemically induced murine tumor.. PubMed. 13(4). 1819–23. 6 indexed citations
17.
Schirrmacher, Santo Landolfo, Rainer Zawatzky, & Holger Kirchner. (1981). Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction and cytotoxic response.. PubMed. 1(3). 175–94. 17 indexed citations
18.
Kindred, Berenice, et al.. (1980). The relationship between alloantigen responses in nude mice injected with a low number of congenic thymus cells.. PubMed. 2(2). 83–92. 1 indexed citations
19.
Schirrmacher, et al.. (1980). Foreign H-2-like molecules on a murine tumor (MCG4): target antigens for alloreactive cytolytic T lymphocytes (CTL) and restricting elements for virus-specific CTL.. PubMed. 12(1). 32–7. 6 indexed citations
20.
Schirrmacher & H Festenstein. (1975). A radioassay for the study of cell surface determinants on activated lymphocytes.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 21(6). 437–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026